The Journal of international medical research · 2014
Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Katabami Takuyuki, Murakami Mariko, Kobayashi Suzuko, Matsui Tomoya, Ujihara Makoto, Takagi Sachiko, Higa Mariko, Ichijo Takamasa, Ohta Akio, Tanaka Yasushi
Аннотация
OBJECTIVE: To analyse the efficacy of low-dose rosuvastatin for treating hypo high-density lipoprotein (HDL) cholesterolaemia in patients with type 2 diabetes and dyslipidaemia.
METHODS: Patients with HDL-cholesterol (C) < 40 mg/dl and triglycerides (TG) < 400 mg/dl who were receiving treatment with lipid-lowering drugs other than rosuvastatin (or previously untreated with lipid-lowering drugs) and with low-density lipoprotein [LDL]-C ≥ 120 mg/dl were included. Patients were treated with 2.5 or 5 mg rosuvastatin orally, once daily, to achieve the target LDL-C level specified in Japanese guidelines. Changes in total cholesterol, HDL-C, TG, LDL-C, LDL-C/HDL-C and non-HDL-C at 3 and 6 months were prospectively analysed. Safety was evaluated by examining changes in hepatorenal function, glucose metabolism and creatine kinase.
RESULTS: Out of 49 patients, all lipid parameters other than TG were significantly improved at 3 and 6 months. At 3 months, 83.3% of patients had achieved the target LDL-C level. Among nonlipid parameters, no changes were observed except for estimated glomerular filtration rate, which was improved by + 5.2% and + 9.6% at 3 and 6 months, respectively.
CONCLUSIONS: Low-dose rosuvastatin was effective in improving hypo-HDL cholesterolaemia and may have renoprotective effects.
METHODS: Patients with HDL-cholesterol (C) < 40 mg/dl and triglycerides (TG) < 400 mg/dl who were receiving treatment with lipid-lowering drugs other than rosuvastatin (or previously untreated with lipid-lowering drugs) and with low-density lipoprotein [LDL]-C ≥ 120 mg/dl were included. Patients were treated with 2.5 or 5 mg rosuvastatin orally, once daily, to achieve the target LDL-C level specified in Japanese guidelines. Changes in total cholesterol, HDL-C, TG, LDL-C, LDL-C/HDL-C and non-HDL-C at 3 and 6 months were prospectively analysed. Safety was evaluated by examining changes in hepatorenal function, glucose metabolism and creatine kinase.
RESULTS: Out of 49 patients, all lipid parameters other than TG were significantly improved at 3 and 6 months. At 3 months, 83.3% of patients had achieved the target LDL-C level. Among nonlipid parameters, no changes were observed except for estimated glomerular filtration rate, which was improved by + 5.2% and + 9.6% at 3 and 6 months, respectively.
CONCLUSIONS: Low-dose rosuvastatin was effective in improving hypo-HDL cholesterolaemia and may have renoprotective effects.
Предметные рубрики MeSH
AdultAgedAged, 80 and overAnticholesteremic AgentsCholesterol, HDLCholesterol, LDLCreatine KinaseDiabetes Mellitus, Type 2DyslipidemiasFemaleFluorobenzenesGlucoseHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsLipoproteins, HDLMaleMiddle AgedProspective StudiesPyrimidinesRosuvastatin CalciumSulfonamidesTriglyceridesYoung Adult